<SEC-DOCUMENT>0000950170-25-004846.txt : 20250113
<SEC-HEADER>0000950170-25-004846.hdr.sgml : 20250113
<ACCEPTANCE-DATETIME>20250113162453
ACCESSION NUMBER:		0000950170-25-004846
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250113

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Olema Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001750284
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				300409740
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91849
		FILM NUMBER:		25526631

	BUSINESS ADDRESS:	
		STREET 1:		780 BRANNAN STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94103
		BUSINESS PHONE:		(415) 651-3316

	MAIL ADDRESS:	
		STREET 1:		780 BRANNAN STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94103

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bain Capital Life Sciences Opportunities IV, L.P.
		CENTRAL INDEX KEY:			0002015553
		ORGANIZATION NAME:           	
		IRS NUMBER:				933199560
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		200 CLARENDON STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		6175162000

	MAIL ADDRESS:	
		STREET 1:		200 CLARENDON STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001193125-24-275608</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0002015553</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>1</amendmentNo>
<securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>01/08/2025</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001750284</issuerCik>
<issuerName>OLEMA PHARMACEUTICALS, INC.</issuerName>
<issuerCusip>68062P106</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">780 Brannan Street</street1>
<city xmlns="http://www.sec.gov/edgar/common">San Francisco</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">94103</zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>
<reportingPersonName>Bain Capital Life Sciences Opportunities IV, L.P.</reportingPersonName>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>7095780</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>7095780</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>7095780</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>9.99</classPercent>
<typeOfReportingPerson>PN</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>OLEMA PHARMACEUTICALS, INC.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>780 Brannan Street, San Francisco, California 94103</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>This Schedule 13G is being filed by Bain Capital Life Sciences Opportunities IV, L.P., a Delaware limited partnership (the "Reporting Person"). Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company ("BCLSI"), is the manager of Bain Capital Life Sciences IV General Partner, LLC, a Delaware limited liability company ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P., a Delaware limited partnership ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC, a Delaware limited liability company (together with the Reporting Person, BCLSI, BCLS Fund IV GP and BCLS Fund IV, the "Bain Capital Life Sciences Entities"), which is the general partner of the Reporting Person. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person.</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116.</principalBusinessOfficeOrResidenceAddress>
<citizenship>Each of the Bain Capital Life Sciences Entities is organized under the laws of the State of Delaware.</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>As of the date hereof, the Reporting Person holds 4,400,000 shares of Common Stock and pre-funded warrants to purchase up to 8,013,216 shares of Common Stock. The Reporting Person is prohibited from exercising the pre-funded warrants if, as a result of such exercise, the Reporting Person would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Blocker"). Accordingly, pursuant to Rule 13d-3 of the Act, the Reporting Person may be deemed to beneficially own 9.99% of the outstanding shares of Common Stock, representing 7,095,780 shares of Common Stock. The percentage of the outstanding shares of Common Stock held by the Reporting Person is based on (i) 68,333,065 shares of Common Stock issued and outstanding, as reported by the Issuer in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 10, 2025 and (ii) 2,695,780 shares of Common Stock issuable upon the partial exercise of the pre-funded warrants held by the Reporting Person, which reflects the Beneficial Ownership Blocker.</amountBeneficiallyOwned>
<classPercent>See Item 4(a) hereof.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>0</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>See Item 4(a) hereof.</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>See Item 4(a) hereof.</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.
</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>Bain Capital Life Sciences Opportunities IV, L.P.</reportingPersonName>
<signatureDetails>
<signature>/s/ Andrew Hack</signature>
<title>Partner</title>
<date>01/13/2025</date>
</signatureDetails>
</signatureInformation>
<signatureComments>* By: Bain Capital Life Sciences Opportunities IV GP, LLC, its general partner; By: Bain Capital Life Sciences Fund IV, L.P., its sole member; By: Bain Capital Life Sciences IV General Partner, LLC, its general partner; By: Bain Capital Life Sciences Investors, LLC, its manager</signatureComments>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
